Abbott announces the acquisition of Exact Sciences, a leader in cancer screening and precision oncology diagnostics segments.
The acquisition will add a new growth vertical to Abbott's portfolio, gaining leadership in the fast-growing U.S. cancer screening and precision oncology diagnostics segments.
Exact Sciences' product lines include market-leading tests like Cologuard® and Oncotype DX® for advanced cancer screening and molecular residual disease testing.
Strategic Acquisition
Entering the fast-growing cancer diagnostics segments will enhance Abbott's growth profile.
Innovative Solutions
Exact Sciences' advanced tests enable earlier cancer detection and personalized treatment decisions.
Financial Impact
The acquisition is expected to be immediately accretive to Abbott's revenue growth and gross margin.
Revenue Projection
Exact Sciences projected to generate over $3 billion in revenue with high teens organic sales growth.
- The acquisition will position Abbott to transform cancer care by advancing earlier detection and optimizing treatment, benefiting millions of individuals.
- Abbott's total diagnostics sales are anticipated to exceed $12 billion annually following the completion of the transaction.
The acquisition of Exact Sciences marks a significant step for Abbott in expanding its presence in cancer diagnostics, aligning with its mission to improve healthcare outcomes through innovative solutions.